CYP2E1 and NQO1 genotypes and bladder cancer risk in a Lebanese population

International Journal of Molecular Epidemiology and Genetics

Volumn 4, Issue 4, 2013, Pages 207-217

  Basma, Hussein A ^a   Kobeissi, Loulou H ^b   Jabbour, Michel E ^c   Moussa, Mohamad A ^d   Dhaini, Hassan R ^a  

^a UNIVERSITY OF BALAMAND   (Lebanon)

^b UNIVERSITY OF ARIZONA   (United States)

^c SAINT GEORGE HOSPITAL UNIVERSITY MEDICAL CENTER   (Lebanon)

^d Bahman Hospital   (Lebanon)

Author keywords

Bladder cancer; Cytochrome P450 CYP2E1; Lebanese; N Acetyltransferase NAT1; NQO1

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450 2E1; NADPH QUINONE OXIDOREDUCTASE1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

AGED; ALLELE; ARTICLE; BLADDER CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SMOKING;

EID: 84889666238     PISSN: 19481756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C and Parkin D. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Ploeg M, Aben K and Kiemeney L. The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27: 289-293.
3. Jemal R, Bray F, Center M, Ferlay J, Ward E and Forman D. Global Cancer Statistics. CA Cancer J Clin 2011; 61: 69-90.
4. Shamseddine A, Sibai A, Gehchan N, Rahal B, El-Saghir N, Ghosn M, Aftimos G, Chamsuddine N and Seoud M. Cancer incidence in postwar Lebanon: findings from the first national population-based registry, 1998. Ann Epidemiol 2004; 14: 663-668.
5. World Health Organization. Combating the tobacco epidemic. Geneva: WHO, 1999.
6. Lebanese Ministry of Public Health and Epidemiology Surveillance Program. National Cancer Registry Report Cancer Data 2007. http://www.moph.gov.lb/Prevention/Surveillance/Pages/Cancer.aspx: MOPH, 2010.
7. Adib S, Daniel J and Issa G. Cancer in Lebanon 2004, with an update of Cancer 2003. http://www.moph.gov.lb/Prevention/Surveillance/Pages/Cancer.aspx: Lebanese Ministry of Public Health, 2008.
8. Stiborova M, Levova K, Barta F, Shi Z, Frei E, Schmeiser HH, Nebert DW, Phillips DH and Arlt VM. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol Sci 2012; 125: 345-358.
9. Sato M, Sato T, Izumo T and Amagasa T. Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis 1999; 20: 1927-1931.
10. Sheweita SA, Abu El-Maati MR, El-Shahat FG and Bazeed MA. Changes in the expression of cytochrome P450 2E1 and the activity of carcinogen-metabolizing enzymes in Schistosoma haematobium-infected human bladder tissues. Toxicology 2001; 162: 43-52.
11. Hou DF, Wang SL, He ZM, Yang F and Chen ZC. Expression of CYP2E1 in human nasopharynx and its metabolic effect in vitro. Mol Cell Biochem 2007; 298: 93-100.
12. Feng J, Pan X, Yu J, Chen Z, Xu H, El-Rifai W, Zhang G and Xu Z. Functional PstI/RsaI polymorphism in CYP2E1 is associated with the development, progression and poor outcome of gastric cancer. PLoS One 2012; 7: e44478.
13. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, Wakui A, Kanamaru R and Watanabe M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 1991; 82: 254-256.
14. Hayashi S, Watanabe J and Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991; 110: 559-565.
15. Peng H, Xie SK, Huang MJ and Ren DL. Associations of CYP2E1 rs2031920 and rs3813867 polymorphisms with colorectal cancer risk: a systemic review and meta-analysis. Tumour Biol 2013; 34: 2389-2395.
16. Tian Z, Li YL, Zhao L and Zhang CL. CYP2E1 RsaI/PstI polymorphism and liver cancer risk among east Asians: a HuGE review and meta-analysis. Asian Pac J Cancer Prev 2012; 13: 4915-4921.
17. Choi JY, Lee KM, Cho SH, Kim SW, Choi HY, Lee SY, Im HJ, Yoon KJ, Choi H, Choi I, Hirvonen A, Hayes RB and Kang D. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 2003; 13: 349-355.
18. Cai L, Zheng ZL and Zhang ZF. Cytochrome p450 2E1 polymorphisms and the risk of gastric cardia cancer. World J Gastroenterol 2005; 11: 1867-1871.
19. Sangrajrang S, Jedpiyawongse A and Srivatanakul P. Genetic polymorphisms of CYP2E1 and GSTM1 in a Thai population. Asian Pac J Cancer Prev 2006; 7: 415-419.
20. Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ and Ross D. NAD(P)H: quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 2004; 65: 1238-1247.
21. Radjendirane V, Joseph P, Lee YH, Kimura S, Klein-Szanto AJ, Gonzalez FJ and Jaiswal AK. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem 1998; 273: 7382-7389.
22. Dinkova-Kostova AT and Talalay P. NAD(P)H: quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 2010; 501: 116-123.
23. Chao C, Zhang ZF, Berthiller J, Boffetta P and Hashibe M. NAD(P)H: quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 979-987.
24. Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC and McLeod H. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 2002; 21: 1119-1124.
25. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R and Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63: 2649-2657.
26. Siegel D and Ross D. Immunodetection of NAD(P)H: quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 2000; 29: 246-253.
27. Nebert DW, Roe AL, Vandale SE, Bingham E and Oakley GG. NAD(P)H: quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 2002; 4: 62-70.
28. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D and Gibson NW. NAD(P)H: quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992; 52: 797-802.
29. Siegel D, McGuinness SM, Winski SL and Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H: quinone oxidoreductase 1. Pharmacogenetics 1999; 9: 113-121.
30. Terry PD, Umbach DM and Taylor JA. No association between SOD2 or NQO1 genotypes and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 753-754.
31. Park SJ, Zhao H, Spitz MR, Grossman HB and Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 2003; 536: 131-137.
32. Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, Carta A, Hautefeuille A and Porru S. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 2004; 25: 973-978.
33. Butcher N, Ilett K and Minchin R. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. Pharmacogenetics 1998; 8: 67-72.
34. Dhaini H and Levy G. Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population. Pharmacogenetics 2000; 10: 79-83.
35. Hughes N, Janezic S, McQueen K, Jewett M, Castranio T, Bell D and Grant D. Identification and characterization of variant alleles of human acetyltranferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998; 8: 55-66.
36. Yassine IA, Kobeissi L, Jabbour ME and Dhaini HR. N-Acetyltransferase 1 (NAT1) Genotype: A Risk Factor for Urinary Bladder Cancer in a Lebanese Population. J Oncol 2012; 2012: 512976.
37. Kobeissi LH, Yassine IA, Jabbour ME, Moussa MA and Dhaini HR. Urinary bladder cancer risk factors: a lebanese case-control study. Asian Pac J Cancer Prev 2013; 14: 3205-3211.
38. El Saghir NS, Adib S, Mufarrij A, Kahwaji S, Taher A, Issa P and Shamseddine AI. Cancer in Lebanon: analysis of 10,220 cases from the American University of Beirut Medical Center. J Med Liban 1998; 46: 4-11.
39. Salim E, Moore M, Bener A, Habib O, Seif-Eldin I and Sobue T. Cancer epidemiology in South-West Asia-past, present and future. Asian Pac J Cancer Prev 2010; 11 Suppl 2: 33-48.
40. Shamseddine A and Musallam K. Cancer Epidemiology in Lebanon. Middle East Journal of Cancer 2010; 1: 41-44.
41. Anwar W, AbdelRahman S, El-Zein R, Mostafa H and Au W. Genetic polymorphism of GSTM1, CYP2E1, and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 1996; 17: 1923-1929.
42. Mittal RD, Srivastava DS, A M and B M. Genetic polymorphism of drug metabolizing enzymes (CYP2E1, GSTP1) and susceptibility to bladder cancer in North India. Asian Pac J Cancer Prev 2005; 6: 6-9.
43. Brockmoller J, Cascorbi I, Kerb R and Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione-S-transferase M1, and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56: 3915-3925.
44. Farker K, Lehmann MH, Oelschlagel B, Haerting J, Hoffmann A, Janitzky V and Schubert J. Impact of CYP2E1 genotype in renal cell and urothelial cancer patients. Exp Toxicol Pathol 1998; 50: 425-431.
45. Zgheib NK, Mitri Z, Geryess E and Noutsi P. Cytochrome P4502E1 (CYP2E1) genetic polymorphisms in a Lebanese population: frequency distribution and association with morbid diseases. Genet Test Mol Biomarkers 2010; 14: 393-397.
46. Bolt HM, Roos PH and Thier R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int Arch Occup Environ Health 2003; 76: 174-185.
47. Kayaalti Z and Soylemezoglu T. Distribution of ADH1B, ALDH2, CYP2E1*6, and CYP2E1*7B genotypes in Turkish population. Alcohol 2010; 44: 415-423.
48. Shahriary GM, Galehdari H, Jalali A, Zanganeh F, Alavi SM and Aghanoori MR. CYP2E1*5B, CYP2E1*6, CYP2E1*7B, CYP2E1*2, and CYP2E1*3 Allele Frequencies in Iranian Populations. Asian Pac J Cancer Prev 2012; 13: 6505-6510.
49. Liu S, Park JY, Schantz SP, Stern JC and Lazarus P. Elucidation of CYP2E1 5' regulatory RsaI/Pstl allelic variants and their role in risk for oral cancer. Oral Oncol 2001; 37: 437-445.
50. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, Katoh T, Kamataki T, Kawamura J, Yatani R and Shiraishi T. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001; 165: 171-177.
51. Kato S, Shields P, Caporaso N, Hoover R, Trump B, Sugimura H, Weston A and Harris C. Cytochrome P450 IIE1 geneteic polymorphisms, racial variation, and lung cancer risk. Cancer Res 1992; 52: 6712-6715.
52. Lewis SJ, Cherry NM, Niven RM, Barber PV and Povey AC. Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer 2001; 34: 177-183.
53. Xu LL, Wain JC, Miller DP, Thurston SW, Su L, Lynch TJ and Christiani DC. The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev 2001; 10: 303-309.
54. Schulz WA, Krummeck A, Rosinger I, Eickelmann P, Neuhaus C, Ebert T, Schmitz-Drager BJ and Sies H. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997; 7: 235-239.
55. Wiencke JK, Spitz MR, McMillan A and Kelsey KT. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 1997; 6: 87-92.
56. Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo ZF, Spitz MR, Wang M, Xu X, Lee BK, Schwartz BS and Wiencke JK. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 1997; 76: 852-854.
57. Salem AH, Yaqoob A, Ali M, Handu S, Fadel R, Abu-Hijleh M and Almawi W. Genetic polymorphism of the glutathione S-transferase M1 and T1 genes in three distinct Arab populations. Dis Markers 2011; 31: 311-316.
58. Pandith AA, Khan NP, Shah ZA, Shah AM, Wani SM and Siddiqi MA. Association of bladder cancer risk with an NAD(P)H: quinone oxidoreductase polymorphism in an ethnic Kashmiri population. Biochem Genet 2011; 49: 417-426.
59. Gong M, Yi Q and Wang W. Association between NQO1 C609T polymorphism and bladder cancer susceptibility: a systemic review and meta-analysis. Tumour Biol 2013; 34: 2551-6.
60. Ovsiannikov D, Selinski S, Lehmann ML, Blaszkewicz M, Moormann O, Haenel MW, Hengstler JG and Golka K. Polymorphic enzymes, urinary bladder cancer risk, and structural change in the local industry. J Toxicol Environ Health A 2012; 75: 557-565.
61. Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR, Schwenn MR, Johnson AT, Lubin JH, Hein DW, Dagnall CL, Colt JS, Kida M, Jones MA, Schned AR, Cherala SS, Chanock SJ, Cantor KP, Silverman DT and Rothman N. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis 2011; 32: 182-189.
62. Cantor KP, Villanueva CM, Silverman DT, Figueroa JD, Real FX, Garcia-Closas M, Malats N, Chanock S, Yeager M, Tardon A, Garcia-Closas R, Serra C, Carrato A, Castano-Vinyals G, Samanic C, Rothman N and Kogevinas M. Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection by-products, and risk of bladder cancer in Spain. Environ Health Perspect 2010; 118: 1545-1550.